

Edinburgh, 21 January 2022

**Medannex's monoclonal antibody MDX-124 highly active
in pancreatic cancer models**

Data shows powerful synergy in combination with standard cancer treatments

Medannex Ltd (Edinburgh) today announced new data for their first-in-class targeted agent, MDX-124, showing significant anti-tumour activity in preclinical pancreatic cancer models. The results were released at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium in San Francisco, USA.

MDX-124 induces cell cycle arrest, preventing cancer cells progressing from the growth phase (G1) to the DNA synthesis phase (S). This causes a significant reduction in cancer cell proliferation and greatly increases primary tumour necrosis. Furthermore, MDX-124 significantly decreases cancer cell migration, and reduces both the incidence and burden of metastatic spread – the major cause of cancer mortality.

In December, Medannex released data showing MDX-124 has potent activity in breast cancer models and significant synergy when combined with widely used chemotherapies cisplatin and paclitaxel. Today's data demonstrate synergy between MDX-124 and two additional chemotherapies, 5-FU and gemcitabine, which are standard-of-care treatments for several cancers, including pancreatic.

Professor Daniel Palmer, of the University of Liverpool's Department of Molecular and Clinical Cancer Medicine, commented: 'Pancreatic cancer is incredibly challenging and we desperately need new therapies. These non-clinical data suggest that MDX-124 could provide a new treatment option as a single agent or in combination with established cancer therapies and clinical trials are now eagerly anticipated.'

Medannex CEO Ian Abercrombie said: 'We are very encouraged by these data, especially the impressive added benefit when combining MDX-124 with established cancer drugs. This demonstrates great potential for our agent to improve outcomes for patients. We look forward to exploring this further in our imminent First-in-Human study, which will include patients with pancreatic cancer.'

The new data were generated by Medannex in collaboration with the University of Liverpool, ARU (Cambridge) and Brighton & Sussex Medical School, and can be viewed in full here:

<https://medannex.org/wp-content/uploads/2022/01/220110-ASCO-GI-2022-Poster-Final.pdf>

About Medannex Ltd: Medannex is a privately-owned biopharmaceutical company registered in Scotland, with headquarters in Edinburgh. The company is developing novel treatments to improve the lives of people suffering from cancers and autoimmune diseases, and is currently engaging with investors regarding a Series C fundraise: <https://medannex.org>

About MDX-124: MDX-124 is a humanised monoclonal antibody, and the first agent to specifically target and inhibit annexin-A1, a protein known to play a key role in the development of cancers, autoimmune diseases and other conditions.

- ENDS -

Medannex Ltd enquiries – email jamesingham@medannex.org